Sugi Predict

Sugi Predict / Compounds / SCHEMBL21189712

SCHEMBL21189712

SCHEMBL21189712

COc1ccc(Br)cc1C(=O)N(C)C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.60
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ MAPT P10636 3/20 0.52
▸ CYP1A2 P05177 2/20 0.52
▸ CYP2C9 P11712 2/20 0.52
▸ CYP2C19 P33261 2/20 0.52
▸ GFER P55789 1/20 0.52
▸ HSD17B10 Q99714 1/20 0.52
▸ POLB P06746 4/20 0.50
▸ RECQL P46063 1/20 0.49
▸ STAT3 P40763 1/20 0.49
▸ KDM4E B2RXH2 2/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.48
▸ NPSR1 Q6W5P4 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ KMT2A Q03164 3/20 0.45
▸ HTT P42858 2/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ HPGD P15428 1/20 0.45
▸ AR P10275 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6270450 0.87 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2MAPTCYP1A2CYP2C9
SCHEMBL18340040 0.86 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTCYP1A2CYP2C9
SCHEMBL25078397 0.82 ACHE (0.50) ALDH1A1SMN1; SMN2MAPTHSD17B10POLB
SCHEMBL1221627 0.82 POLB (0.63) ALDH1A1SMN1; SMN2MAPTCYP1A2CYP2C9
SCHEMBL30362007 0.82 POLB (0.63) ALDH1A1SMN1; SMN2MAPTCYP1A2CYP2C9
SCHEMBL21177597 0.82 POLB (0.48) ALDH1A1SMN1; SMN2MAPTCYP1A2CYP2C9
SCHEMBL7511970 0.81 MAPT (0.62) ALDH1A1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL1821903 0.80 PTGDR2 (0.63) ALDH1A1SMN1; SMN2MAPTCYP1A2CYP2C9
Hydrochloric Acid SCHEMBL27134662 0.80 POLB (0.61) ALDH1A1SMN1; SMN2MAPTCYP1A2CYP2C9
SCHEMBL18740487 0.80 TP53 (0.50) ALDH1A1SMN1; SMN2MAPTCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4667458-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG Kanaph Therapeutics Inc. (KR) 2025-12-24 — — EP disclosed
US-20240400518-A1 SOS1 INHIBITOR AND USE THEREOF CYRUS THERAPEUTICS INC. (KR) 2024-12-05 — — US disclosed
US-20240336618-A1 PI4KIIIBETA INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-10-10 — — US disclosed
WO-2024172631-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG 주식회사 카나프테라퓨틱스 2024-08-22 — — WO disclosed
EP-4389738-A1 SOS1 INHIBITOR AND USE THEREOF Kanaph Therapeutics Inc. (KR) 2024-06-26 — — EP disclosed
CN-118119600-A SOS1 inhibitors and uses thereof 治纳辅医药科技有限公司 2024-05-31 — — CN disclosed
CN-111868063-B PI4KIII beta inhibitors 葛兰素史克知识产权开发有限公司 2023-08-01 — — CN disclosed
US-11649238-B2 Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-05-16 — — US disclosed
US-11649238-B2 Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-05-16 — — US disclosed
US-11649238-B2 Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-05-16 — — US disclosed
US-20230124394-A1 PI4KIIIBETA INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-20 — — US disclosed
US-20230124394-A1 PI4KIIIBETA INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-20 — — US disclosed
WO-2023022497-A1 SOS1 INHIBITOR AND USE THEREOF 주식회사 카나프테라퓨틱스 2023-02-23 — — WO disclosed
WO-2023022497-A1 SOS1 INHIBITOR AND USE THEREOF 주식회사 카나프테라퓨틱스 2023-02-23 — — WO disclosed
US-20210387988-A1 PI4KIIIbeta Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-12-16 — — US disclosed
US-20210387988-A1 PI4KIIIbeta Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-12-16 — — US disclosed
EP-3740489-A1 PI4KIIIBETA INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2020-11-25 — — EP disclosed
CN-111868063-A PI4KIII beta inhibitors 葛兰素史克知识产权开发有限公司 2020-10-30 — — CN disclosed
WO-2019141694-A1 PI4KIIIBETA INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-07-25 — — WO disclosed
WO-2019141694-A1 PI4KIIIBETA INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-07-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230124394-A1 PI4KIIIBETA INHIBITORS PI4KB, PI4K2B, PI4K2A ALDH1A1 4847/4885SMN1; SMN2 4317/4885MAPT 2882/4885
US-11649238-B2 Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors PI4K2A, PI4K2B, PI4KA ALDH1A1 4417/4885SMN1; SMN2 4271/4885MAPT 2830/4885
US-20240336618-A1 PI4KIIIBETA INHIBITORS PI4KB, PI4K2B, PI4K2A ALDH1A1 4857/4885SMN1; SMN2 4375/4885MAPT 2958/4885
US-20210387988-A1 PI4KIIIbeta Inhibitors PI4KB, PI4K2B, PI4K2A ALDH1A1 4857/4885SMN1; SMN2 4375/4885MAPT 2958/4885
US-20240400518-A1 SOS1 INHIBITOR AND USE THEREOF SOS1, RAC1, SOS2 ALDH1A1 3325/4885SMN1; SMN2 785/4885MAPT 3803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.